• Nanjing Leads Biolabs flagged a potential catalyst as it secured Late-Breaking Abstract status for ESMO 2026, with the full submission due in September.
• Six studies were accepted for ESMO 2026, including two Proffered Paper oral presentations, supporting visibility for key pipeline assets.
• Opamtistomig in first-line NSCLC was also selected for an oral presentation at WCLC 2026, with the abstract scheduled for Aug. 19 publication.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: CN02750) on July 13, 2026, and is solely responsible for the information contained therein.